Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer

Qing Chang1, Igor Jurisica1,2, Trevor Do1, and David W. Hedley1,2,3

Abstract

Hypoxia in solid tumors is associated with treatment resistance and increased metastatic potential. Although hypoxia has been reported in pancreatic cancer patients, there is little direct evidence that this contributes to their overall poor prognosis. To address this, we examined the associations between hypoxia and biological aggression in a series of patient-derived xenografts grown orthotopically. Early passage xenografts were established from 16 patients undergoing surgery for pancreatic cancer and maintained in the pancreas of immune-deprived mice. Hypoxic cells were labeled using the 2-nitroimidazole probe EF5 and stained for immunofluorescence microscopy of tissue sections or as cell suspensions for flow cytometry. Bromodeoxyuridine (BrdUrd) uptake, microvessel density, cleaved caspase-3, and the differentiation markers E-cadherin, cytokeratin 19, and vimentin were analyzed in relation to hypoxia. Orthotopic implants closely resembled the histology of the original surgical samples. The 16 primary xenografts showed a wide range in their growth rates and metastatic potential, reminiscent of the spectrum of behavior seen in the clinic. EF5 labeling, tumor growth rates, and metastatic patterns were highly consistent within replicates, indicating a significant transmissible (genetic or epigenetic) component. Hypoxia was highly correlated with rapid tumor growth, increased BrdUrd uptake, and with spontaneous metastasis formation. mRNA expression analysis showed increased expression of genes involved in cell survival and proliferation in the hypoxic models. The results suggest that hypoxia is a major adverse prognostic factor in pancreatic cancer patients and support the introduction of techniques to measure hypoxia directly in patients and the development of treatment protocols to target hypoxia.

Cancer Res; 71(8); 3110–20. ©2011 AACR.

Introduction

Hypoxia occurs in solid tumors when the consumption of oxygen exceeds its delivery by the vascular system (1). In most large clinical studies, the outcome is worse for patients with hypoxic tumors, consistent with the long-held idea that hypoxia confers both radiation and chemotherapy resistance (2–4). Unexpectedly, high levels of tumor hypoxia were also found to predict metastasis development in patients treated by surgery alone, pointing to biological effects beyond those linked to drug and radiation resistance (5, 6). The hypoxic microenvironment is hostile to cancer cell survival. Hypoxia tolerance can occur due to genetic changes such as p53 loss that enhance cell survival (7), or due to cellular responses to hypoxia, driven, for example, by hypoxia-inducible factors (HIF) or the unfolded protein response, that modify gene expression, cell phenotype, and metabolism (8, 9). In a recent article describing the genetic evolution of pancreatic cancers, it was suggested that cancer cells adapted to hypoxia could undergo additional genetic changes that enhance metastasis formation (10). In other words, hypoxia might be a cause of genetic change, as well as a consequence.

The increased metastatic potential of hypoxic cancers might result from changes in cell biology that are mediated by cellular responses to hypoxia (11–13). For example, growth under hypoxic conditions may reprogram epithelial cells toward a more mesenchymal phenotype due to the activation of E-cadherin transcriptional repressors (12, 14, 15). Cells undergoing epithelial-to-mesenchymal transition (EMT) show reduced cell–cell interaction via adherens junctions and increased extracellular matrix interactions via integrins/local adhesion kinase. Consequently, they are more motile and can invade and metastasize (16, 17). Successful development of a metastasis presumably requires at least 1 cancer-initiating cell. Pancreatic cancer stem cells have been reported to show EMT features (18, 19), and it has also been proposed that...
hypoxia provides a niche that favors the survival of cancer cells with stem-like properties (20–22).

Although pancreatic cancers are often considered as being hypoxic, most publications have used histologic surrogate markers for hypoxia that might be compromised by surgical ischemic time or by sampling error due to the heterogeneous distribution of hypoxia in tumor tissue (23, 24). Direct evidence that pancreatic cancers are hypoxic is limited to a small study in which intraoperative \( \text{PO}_3 \) measurements were made by inserting needle electrodes into the exposed tumor (25). To address the question of whether hypoxia plays an important role in pancreatic cancer patients, we studied a series of early passage xenografts established from pancreatectomy samples and grown orthotopically. The results show striking associations between hypoxia and aggressive growth and metastasis formation.

Materials and Methods

Establishment of orthotopic primary pancreatic cancer xenografts

Animal experiments were carried out using protocols approved by University Health Network Animal Welfare Committee. The primary pancreatic cancer xenografts were established as previously described (26–29). Fresh pancreatectomy samples that were superfluous to diagnostic needs were obtained from the University Health Network Tumor Tissue Bank according to institutional ethical guidelines. Primary xenografts were established at the orthotopic site of 4- to 5-week-old severe combined immunodeficiency mice by attaching tumor fragments to the surface of the exposed pancreas by a small incision in the upper left abdomen under general anesthesia. Sixteen orthotopic primary pancreatic cancer xenografts, designated as Ontario Cancer Institute Pancreas (OCIP) 16, 18, 19, 20, 21, 23, 24, 28, 30, 34, 36, 37, 38, 40, 51, and 52, were used in this study. A minimum of 6 replicate tumors were used for each model.

Detection of tumor hypoxia and proliferation

To allow assessment of the hypoxic regions within tumors, mice were injected intravenously and intraperitoneally (i.p.) with the 2-nitroimidazole hypoxia marker agent EF5 (30 mg/kg) 4 hours prior to sacrifice, as described previously (30, 31). They were then injected i.p. with 100 mg/kg 5-bromo-2'-deoxyuridine (BrdUrd; Sigma) dissolved in PBS 30 minutes prior to sacrifice. Tumors without EF5 and BrdUrd injection were used as negative controls for each model. Tumors were labeled for fluorescence microscopy, using primary antibodies against BrdUrd (Caltag), CD31 (Santa Cruz Biotechnology), cleaved caspase-3 (Cell Signaling Technology), E-cadherin (Vector Laboratories), and vimentin (American Research Products), respectively, and then dual labeled with an anti-EF5–Cy3 conjugate. Secondary Cy5-conjugated anti-mouse or anti-rabbit antibodies were used for indirect immunofluorescence staining (Jackson Laboratories). Secondary antibodies were used alone to control for nonspecific background. Sections were counterstained with 1 \( \mu \text{g/mL} \) DAPI to outline the nuclear area.

Image capture

Entire immunofluorescence-stained sections were imaged at 1-\( \mu \text{m} \) resolution, using a laser scanning system (TISSUEscope; Biomedical Photometrics), and composite images of regions of interest were imaged at higher resolution (magnification \( \times 20 \)), using a conventional fluorescence microscope and scanning stage (BX50; Olympus Corporation). Uncompressed TIFF images (8-bit) were acquired for analysis.

Image analysis

H&E images were reviewed to generate masks of viable tumor areas for individual images of immunofluorescence using image analysis tools developed in-house on the basis of IDL 6.3 programming language. Fluorescence of debris and other artifacts was omitted. Measurements of fluorescence intensity in viable tumor areas were done using Image-Pro Plus 6.1.0 (Media Cybernetics). Immunofluorescence intensity was visually inspected and EF5-positive labeling was represented by intensities above the 75th percentile [the 3rd quartile, (Q3)], as described previously (34). The integrated optical density and fractional labeled area were measured in viable tumor areas by using the Q3 threshold. The product of integrated optical density and fractional labeled area was calculated to represent relative protein abundance. Ratios of protein abundance in EF5-positive region and non-EF5 region of individual tumors were used to determine group
medians. The percentages of positive stained nuclei were measured for BrdUrd and cleaved caspase-3 analyses on the basis of binary images. Researchers were blinded to sample identity during analysis.

Reverse transcription and quantitative PCR
Total RNA was isolated from 3 frozen tumors of each model by homogenization in TRIzol reagent and acid phenol–chloroform extraction, purified by RNeasy mini kit (Qiagen). Reverse transcription was completed at 42°C with SuperScript II RNase H− reverse transcription kit (Invitrogen). Quantitative PCR (qPCR) was conducted with 10 ng of the first-strand cDNA synthesis mixture as a template and individual primer sets (see Supplementary Information), using the SYBR Green PCR Master Mix and an Applied Biosystems 7900 HT instrument. Primers were designed using Primer Express 3.0 (Applied Biosystems). Gene expression levels in the samples were calculated relative to control, using the comparative ΔCt method (35):

\[
\Delta \text{Ct}_{\text{sample}} - \Delta \text{Ct}_{\text{control}}, \text{fold change} = 2^{-\Delta \text{Ct}}.
\]

The geometric mean of GAPDH, β-actin, TATA binding protein, and β-2-microglobulin were used to normalize the expression data (ΔCt).

Protein–protein interaction analysis
Individual genes were mapped to proteins by using Interologous Interaction Database (I2D) version 1.9 (36). Only direct interactions of target proteins and direct interactions among their interactors were considered. The protein–protein interaction network was visualized and annotated in NAViGaTOR version 2.2.1 (37).

Statistical methods
The statistical significance of differences in numerical data was evaluated with a Student’s t test, the statistical significance of correlation between different factors was evaluated with Pearson correlation analysis, and the statistical significance of comparison of survival curves was evaluated with the log-rank test. A P value of less than 0.05 was considered to be statistically significant. All statistical tests were 2-sided.

Results
Characterization of orthotopic primary pancreatic cancer xenografts
Clinicopathologic features and K-ras and p53 mutation status of the 16 patient donors are shown in Table 1. Histologic examination of the H&E sections showed that the orthotopically grown primary xenografts were typically moderately well differentiated, mucin-secreting adenocarcinomas that closely resembled the original surgical specimen (Fig. 1). They were organized into glandular structures, with a prominent fibrovascular stroma replete with α-smooth muscle actin–positive mesenchymal stromal cells (Supplementary Fig. S1). Cellular DNA content analysis by flow

Table 1. Primary pancreatic cancer specimens

<table>
<thead>
<tr>
<th>OCIP#</th>
<th>Diagnosis</th>
<th>Stagea</th>
<th>K-ras mutationb</th>
<th>p53 IHCc</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Ductal ADC, MD</td>
<td>T3N1b</td>
<td>K12, GAT</td>
<td>–</td>
</tr>
<tr>
<td>18</td>
<td>Ductal ADC, MD</td>
<td>T3N0</td>
<td>K12, GAT</td>
<td>–</td>
</tr>
<tr>
<td>19</td>
<td>Ductal ADC, MD</td>
<td>T3N1b</td>
<td>K12, GAT</td>
<td>–</td>
</tr>
<tr>
<td>20</td>
<td>Ductal ADC, WD</td>
<td>T3N1b</td>
<td>K12, GTT</td>
<td>+</td>
</tr>
<tr>
<td>21</td>
<td>Ductal ADC, MD</td>
<td>T3N0</td>
<td>Wild-type</td>
<td>–</td>
</tr>
<tr>
<td>23</td>
<td>Ductal ADC, PD</td>
<td>T3N1b</td>
<td>K12, CGT</td>
<td>+</td>
</tr>
<tr>
<td>24</td>
<td>Ductal ADC, MD</td>
<td>T3N1a</td>
<td>K12, GAT</td>
<td>+</td>
</tr>
<tr>
<td>28</td>
<td>Ductal ADC, WD</td>
<td>T3N0</td>
<td>K12, GTT</td>
<td>–</td>
</tr>
<tr>
<td>30</td>
<td>Ductal ADC, MD</td>
<td>T3N1a</td>
<td>K12, CGT</td>
<td>–</td>
</tr>
<tr>
<td>34</td>
<td>Mucinous cyst ADC and invasive ADSQ</td>
<td>T3N1b</td>
<td>Wild-type</td>
<td>+</td>
</tr>
<tr>
<td>36</td>
<td>Ductal ADC, PD</td>
<td>T2N0</td>
<td>Wild-type</td>
<td>–</td>
</tr>
<tr>
<td>37</td>
<td>Ductal ADC, MD</td>
<td>T3N1b</td>
<td>K12, GAT</td>
<td>–</td>
</tr>
<tr>
<td>38</td>
<td>Ductal ADC, MD</td>
<td>T3N0</td>
<td>K12, GTT</td>
<td>–</td>
</tr>
<tr>
<td>40</td>
<td>Ductal ADC, MD</td>
<td>T3N1b</td>
<td>K12, GTT</td>
<td>–</td>
</tr>
<tr>
<td>51</td>
<td>Ductal ADC, MD</td>
<td>T4N0</td>
<td>K12, GAT</td>
<td>–</td>
</tr>
<tr>
<td>52</td>
<td>Ductal ADC, WD</td>
<td>T3N0M1</td>
<td>K12, GAT</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: ADC, adenocarcinoma; ADSQ, adenosquamous carcinoma; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated.
aTNM classification of tumors of the exocrine pancreas: T2, tumor limited to the pancreas, more than 2 cm in greatest dimension; T3, tumor extends directly into any of the following: duodenum, bile duct, peripancreatic tissues; T4, tumor extends directly into any of the following: stomach, spleen, colon, adjacent large vessels; N0, no regional lymph node metastasis; N1a, metastasis in a single regional lymph node; N1b, metastasis in multiple regional lymph nodes.
bMutation occurs in “codon 12, base transition.”
cImmunohistochemical staining for p53; “+”, positive staining; “−”, negative staining.
BrdUrd incorporation (Hypoxia measurements) assessed by immunofluorescent staining analysis of EF5 labeling, with little overlap between the 2 groups (P = 0.0002) and with spontaneous metastasis formation (P = 0.0003).

**Hypoxia and BrdUrd labeling**

Dual immunofluorescence staining for EF5 and BrdUrd showed a striking loss of BrdUrd incorporation in the EF5-positive regions, indicating that hypoxia causes cell-cycle arrest in these models (Fig. 4A). Interestingly, hypoxia associated with cell-cycle arrest was also seen in small (<1 mm) liver metastases from the hypoxic models, suggesting that this might cause resistance to cell-cycle-active agents such as gemcitabine when used as adjuvant treatment (Fig. 4B). However, as shown in Figure 4C, overall the extent of BrdUrd labeling in the hypoxic models was significantly greater than that seen in the low EF5 staining tumors (P = 0.0002). This apparent paradox is accounted for by higher BrdUrd labeling in the better oxygenated regions of the hypoxic models, as seen in Figure 4A. Hypoxia was also associated with rapid growth (P = 0.0002) and with spontaneous metastasis formation (P = 0.0003).

**Hypoxia and apoptosis**

As shown in Supplementary Figure S3A, cleaved caspase-3 labeling of individual cells showed a heterogeneous distribution that seemed similar in the EF5-negative and -positive areas. However, regions surrounding necrotic areas were often densely populated by cleaved caspase-3-positive cells, as has been previously reported (7). When these regions were excluded, cleaved caspase-3 staining in viable tumor tissue of hypoxic models was significantly higher than in low EF5 staining models (P = 0.0005; Supplementary Fig. S3B).

**Hypoxia and microvessel density**

Consistently in these models, blood vessels were organized in the stroma surrounding the tumor nests and did not invade into masses of tumor tissue (Supplementary Fig. S4A), as has been observed by our group and others using cell line-derived xenografts (39, 40). Microvessel density and the percentage of CD31-positive pixel density obtained from the replicate tumors of 16 models are shown in Supplementary Figure S4B. No significant correlation between hypoxia and either marker of blood vessels was observed in these models.

**Hypoxia and cell differentiation**

Hypoxia has been reported to promote transition toward a more mesenchymal phenotype, associated with increased potential for metastasis (12, 15). We therefore searched for features of EMT in the hypoxic models. Representative dual immunofluorescence staining for EF5 and E-cadherin is shown in Supplementary Figure S5A. In all models tested, the cells within the hypoxic regions showed epithelial features similar to the nonhypoxic regions, including maintenance of apical/basal polarity, surface expression of E-cadherin, and negative staining for vimentin. Single-cell measurements by flow cytometry showed a striking heterogeneity in vimentin expression in the cancer cell population of some models, indicating a degree of plasticity toward expression of a mesenchymal marker (Supplementary Fig. S5B). However, vimentin expression was predominant in EF5-negative cells, indicating that it was not directly linked to hypoxia. Interestingly, vimentin-positive cells coexpressed the epithelial
As shown in Figure 4, there is a strong association between hypoxia, proliferation, and metastasis formation. Because rapid proliferation can cause hypoxia simply by pushing cells away from blood vessels, this might be sufficient to explain the more aggressive behavior of the hypoxic models, as illustrated in Figure 5A (schematic I). Alternatively, hypoxia tolerance might be acquired by some primary xenografts, allowing the accumulation of hypoxic cells that then undergo further reprogramming toward a more invasive or metastatic phenotype (Fig. 5A, schematic II). To explore these alternatives, we selected a panel of genes involved in proliferation, survival, and adaptation to hypoxia that have been previously studied in pancreatic cancers and compared the expression levels in
Figure 3. EF5 measurements by flow cytometry. A, representative plots of EF5 labeling versus DNA content for the 16 primary xenografts. Single-cell suspensions of 16 primary xenografts were fixed, stained with 10 μg/mL EF5–Cy5 conjugates and 1 μg/mL DAPI, and analyzed by flow cytometry. EF5 staining was low or absent in OCIP16, 18, 19, 24, 30, and 40 (top), whereas OCIP20, 21, 23, 28, 34, 36, 37, 38, 51, and 52 showed a heterogeneous distribution of positive staining both in the aneuploid cancer cells and in the normal mouse stroma. B, quantification of EF5 staining by flow cytometry in 6 replicate tumors from 16 primary xenografts.

Discussion

In this article, we identified striking associations between hypoxia and the aggressive features of rapid growth and high metastatic potential in a series of orthotopically grown primary pancreatic cancer xenografts. The highly consistent
results within replicate samples indicate that the underlying mechanisms have a transmissible (genetic or epigenetic) component. This suggests that they reflect, to some extent, biological characteristics of the cancers from which they were derived.

Deficiencies in neovascularization have been linked to the development of hypoxia in some xenograft models, and pancreatic cancers have long been known to show reduced perfusion with radiologic contrast agents (41). However, we did not see a correlation between microvessel density and hypoxia in the primary pancreatic cancer xenografts, suggesting that the failure to develop a vascular system is not directly linked to hypoxia in these tumors.

Within EF5-positive regions, the uptake of BrdUrd was greatly decreased, indicating that hypoxia causes cell-cycle arrest in these tumors. Although there are many previous reports showing this effect in other in vivo models (42, 43), we observed a striking increase in the uptake of BrdUrd in the EF5-negative regions of the hypoxic models, relative to the low hypoxia models, that correlated with their more rapid growth and greater metastatic potential. The hypoxic models also showed a highly significant increase in the number of cells expressing cleaved caspase-3, in both EF5-positive and -negative regions, suggesting that the more rapid cell proliferation was, to some extent, counterbalanced by increased cell loss to apoptosis.

Cell survival is compromised under hypoxic conditions. Hypoxia tolerance can occur due to mutation of genes such as p53 that enhance survival, or through metabolic adaptation in response for example to HIF transcription factors, or the
Figure 5. Gene expression profiling of hypoxic versus nonhypoxic models. A, hypothetical mechanisms to explain the correlations between hypoxia, proliferation, and metastasis. B, mRNA expression of genes involved proliferation, survival, and adaptation to hypoxia by qPCR. P values of comparison of hypoxic (solid black columns) and nonhypoxic models were shown. Each data point represents the mean value of 3 replicate tumors. Error bars, 95% CI.
unfolded protein response. Cells adapted to survive hypoxia might then undergo further alterations toward a phenotype with stem cell–like or invasive properties such as EMT that would favor metastasis. Although our results indicate that hypoxia is insufficient to produce EMT in pancreatic cancers, we cannot exclude the possibility that it may play a role under certain conditions.

The association between hypoxia and increased metastatic potential of pancreatic cancer is novel and of major clinical relevance. However, the extent to which hypoxia is driving metastasis, rather than being the consequence of rapid proliferation, remains uncertain. Rapid proliferation pushes cells away from blood vessels so that they become hypoxic and eventually necrotic. Therefore, it is possible that hypoxia is a bystander effect, and that biological aggression seen in the hypoxic models is being driven by proliferation. However, our preliminary analysis, shown in Figure 5, seems to favor the acquisition of hypoxia tolerance because the hypoxic models show increased expression of genes involved in survival and DNA damage response, as well as HIF1A whose transcriptional activation promotes hypoxia tolerance (8). Furthermore, in preliminary experiments, we found that hypoxia persisted during treatment with an MEK (MAP/ERK kinase) inhibitor that potently inhibits cell-cycle progression (29), suggesting that some degree of hypoxia tolerance exists in these models (Supplementary Fig. S7).

Detailed investigation of the possible genetic mechanisms linking hypoxia to aggressive growth is ongoing, including DNA sequencing as part of the International Cancer Genome Consortium Pancreatic Cancer Genome Project (44).

Clinical implications

Our results predict that the presence of hypoxia in patients undergoing surgical resection for pancreatic cancer carries a high risk of recurrence. Although the follow-up data are limited, we observed a trend for longer survival in the patient donors of the low hypoxia tumors (Supplementary Fig. S8). However, TNM stages for patients enrolled in this study are higher than those that are typical for patients undergoing pancreatectomy (45), probably because insufficient xenograft material was available from early-stage tumors, which may account for the relatively poor survival. To determine the prognostic significance of hypoxia in pancreatic cancer patients, we have started a clinical trial that administers the nitroimidazole probe pimonidazole to patients undergoing pancreatectomy (46, 47). Because primary xenografts are being established from these patients, this study will also allow us to determine the extent to which hypoxia in the patient samples is correlated with hypoxia measurements made in the corresponding primary xenografts.

Regardless of whether hypoxia plays a significant role driving metastasis, or is simply the consequence of rapid growth, BrdUrd-negative cells in hypoxic regions are expected to be resistant to gemcitabine, the mainstay of adjuvant chemotherapy protocols, because this drug is incorporated during S-phase. Significantly, cell-cycle arrest in relation to
hypoxia occurs in early liver metastases from orthotopic primary pancreatic cancer xenografts (Fig. 4B). If these non-cycling cells can reenter the cell cycle following the destruction of proliferating, better oxygenated cells, then the tumor would be expected to repopulate. The overall effect of adjuvant treatment might therefore be to delay cancer recurrence, rather than eliminate all residual cancer cells, and results from randomized clinical trials suggest that this might indeed be the case (48). If so, a logical strategy would be to combine classic chemotherapy drugs such as gemcitabine with bioreducutive agents that show selective toxicity toward hypoxic cells (49, 50).

In conclusion, results shown in this article point toward important mechanisms that link the development of hypoxia to biological aggression in pancreatic cancer patients. Elucidation of the underlying mechanisms is likely to suggest novel therapeutic interventions to improve patient outcome. However, if the results seen in the orthotopic primary xenografts are confirmed in pancreatectomy patients, then they predict that improved patient outcome might be achieved by incorporating hypoxia-targeted agents into existing adjuvant or neoadjuvant treatment protocols, regardless of the underlying molecular mechanisms.

References


Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Drs. Richard P. Hill, Steven Gallinger, and Ming Tsao for many helpful discussions. The authors also thank Pinjiang Cao, Lucy Zhang, Jing Xu, Ni Liu, and Emin Ibrahimov for their excellent technical assistance.

Grant Support

This work was supported by John and Esther Loewen Family Fund and a research grant from the Ontario Institute for Cancer Research. Computational analyses and infrastructure were supported in part by Ontario Research Fund GL2, Canada Foundation for Innovation, Canada Research Chair program, and IBM. This research was funded in part by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the Ontario Ministry of Health and Long Term Care.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 8, 2010; revised January 6, 2011; accepted February 7, 2011; published OnlineFirst February 22, 2011.

www.aacjournals.org


Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer

Qing Chang, Igor Jurisica, Trevor Do, et al.

Cancer Res  Published OnlineFirst February 22, 2011.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-4049

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2011/02/22/0008-5472.CAN-10-4049.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.